As of 2026 there are about six FDA-approved GLP-1 molecules on the market, sold under a longer list of brand names because several are approved twice, once for type 2 diabetes and again for weight management. The lineup includes semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, and the newly approved oral drug orforglipron. Retatrutide, often mentioned alongside these, is not approved and cannot be prescribed. Here is what is real, what is a pill, and what actually separates them.
What does GLP-1 mean, and why do these drugs work?
GLP-1 is a hormone the gut releases after eating. It prompts insulin, slows how fast the stomach empties, and signals fullness to the brain. GLP-1 medications mimic that hormone at its receptor. A 2024 review of these mechanisms describes how the class lowers blood sugar and reduces appetite, and how adding a second receptor target changes the effect. You can read that account of the underlying pharmacology in a 2024 mechanism review. The short version: these are not stimulants or fat blockers. They change hunger and satiety signaling, which is why people eat less without white-knuckling it.
Which single-receptor GLP-1 medications are approved?
The older backbone of the class is the GLP-1-only agonists. Liraglutide arrived first as a daily injection, sold as Victoza for diabetes and Saxenda for weight. Exenatide and dulaglutide are weekly diabetes injections with a longer track record but smaller weight effects than the newer drugs. Semaglutide is the one most people know: Ozempic and oral Rybelsus for diabetes, Wegovy for weight management. Its weight-management effect was established in the STEP program, where trial participants lost a substantial share of body weight over 68 weeks on the higher dose.
Oral semaglutide deserves its own note. It was the first daily GLP-1 pill, though it requires taking it on an empty stomach with strict timing rules that many people find hard to sustain. That inconvenience is part of why a genuinely convenient oral option was so anticipated.
What changed with orforglipron in 2026?
Orforglipron, brand name FOUNDAYO, is the first small-molecule GLP-1 pill approved for weight management, cleared by the FDA in 2026. Unlike oral semaglutide, it is not a peptide, so it does not carry the same food and water restrictions. Early trial work published in 2023 showed meaningful weight reduction in adults with obesity, and later data confirmed the effect in a dedicated obesity population. The details of that later trial appear in a 2025 obesity treatment study, and the approval itself is summarized in the drug’s first approval report. Its earlier phase data is documented in a 2023 report on daily oral orforglipron.
Why does this matter? A once-daily pill without refrigeration or injection changes who is willing to start and stay on treatment. It is not automatically stronger than the injectables, and long-term head-to-head data against tirzepatide does not exist yet. But for people who will not inject, an effective oral option removes the main barrier.
See also: Progress at the Intersection of Tech and Biology
How do the dual-receptor drugs compare?
Tirzepatide is the standout in this group. It acts at both the GIP and GLP-1 receptors, and it is sold as Mounjaro for diabetes and Zepbound for weight management. Its origin as a dual agonist is traced in a 2018 discovery paper. In its own SURMOUNT trials, tirzepatide produced larger average weight reduction than the semaglutide numbers from the STEP trials. That comparison is worth stating carefully: STEP and SURMOUNT were separate studies with different participants and designs, so cross-trial figures suggest a difference rather than prove one. Still, most clinicians treat tirzepatide as the higher-effect option in practice.
A quick map of the approved options
| Molecule | Form | Receptor target | Common brands |
|---|---|---|---|
| Semaglutide | Weekly injection, daily pill | GLP-1 | Ozempic, Wegovy, Rybelsus |
| Tirzepatide | Weekly injection | GIP and GLP-1 | Mounjaro, Zepbound |
| Orforglipron | Daily pill | GLP-1 | FOUNDAYO |
| Liraglutide | Daily injection | GLP-1 | Victoza, Saxenda |
| Dulaglutide | Weekly injection | GLP-1 | Trulicity |
| Exenatide | Weekly injection | GLP-1 | Bydureon |
What about retatrutide and compounded versions?
Retatrutide is a triple receptor agonist still in clinical trials. Its early data has drawn attention, but it is investigational and not approved, so no prescriber can supply it as a finished product in 2026. Treat any offer to sell it as a warning sign.
Compounded semaglutide and tirzepatide are a separate matter. They are prepared by compounding pharmacies rather than manufactured under an approved application, which means they are not FDA-approved products and have not gone through the process behind the trial evidence for the brands. Their appeal is a predictable cash price. Some supervised telehealth practices publish flat monthly pricing and pair it with a prescribing clinician, and one reference that lays out the full list of GLP-1 medications alongside compounded options is the full list of GLP-1 medications, which sits next to named services such as Ro, Hims and Hers, and LillyDirect. The honest read is that compounding trades regulatory assurance for cost, and that trade belongs with a prescriber who knows the case.
How do guidelines frame choosing among them?
Recent guidance treats GLP-1 medications as a mainstream tool rather than a last resort, but with conditions. A 2025 clinical practice guideline update on obesity pharmacotherapy and the AGA guideline on pharmacological obesity interventions both frame drug choice around the whole clinical picture, not weight alone. Newer work is also redefining what obesity means: a 2025 paper on the definition and diagnostic criteria of clinical obesity pushes past body mass index toward function and organ effects. And GLP-1 use is spreading into related conditions, including liver disease, where the EASL-EASD-EASO guidelines on MASLD discuss where these agents fit.
The practical takeaway is that no single drug is best for everyone. Tirzepatide tends to produce the largest weight change, orforglipron removes the injection barrier, and the older agents still make sense for people whose insurance covers them or whose diabetes is the main target.
Key takeaways
- Six approved molecules exist in 2026, but they are sold under many more brand names.
- Orforglipron (FOUNDAYO) is a 2026-approved daily pill, not an injection and not investigational.
- Tirzepatide showed the largest weight effect, though its trials were separate from the semaglutide trials.
- Retatrutide is investigational, and compounded versions are not FDA-approved products.
Frequently asked questions
How many GLP-1 medications are actually available in 2026?
Roughly half a dozen FDA-approved molecules, sold under multiple brand names for diabetes and for weight management. The count depends on whether you separate brand names from active ingredients, since several drugs are marketed twice under different names.
Is there a GLP-1 pill now, or is everything an injection?
Both. Oral semaglutide has been available for years, and orforglipron, a once-daily small-molecule pill, was FDA-approved in 2026 for weight management. Most of the higher-effect options are still weekly injections.
What is the difference between a single and a dual receptor agonist?
A single agonist acts mainly at the GLP-1 receptor. A dual agonist such as tirzepatide also acts at the GIP receptor. In its trials tirzepatide produced larger average weight reduction than the GLP-1-only agents, though the trials were run separately.
Is retatrutide available?
No. Retatrutide is investigational and not approved as of 2026. It is a triple receptor agonist still in clinical trials, so it cannot be prescribed as an approved product.
Are compounded GLP-1 medications the same as the brands?
No. Compounded semaglutide and tirzepatide are prepared by compounding pharmacies and are not FDA-approved products. They may use the same active molecule but have not been through the approval process behind the published trial evidence.
